Emory University’s Aclaris Therapeutics ACRS Stock Holding History

Emory University’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-90,704	Closed	-$2.46M	–	42
2016 Q4	$2.46M	Buy	+90,704	New	+$2.31M	2.42%	2

Other funds holding ACRS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emory University's ACRS Position: Q1 2017 in Review

Emory University sold out of Aclaris Therapeutics (ACRS) in Q1 2017, closing a stake of 90,704 shares — an estimated $2.46M sold.

Emory University first reported a position in ACRS in Q4 2016 and held it in 1 quarter. The position peaked at $2.46M in Q4 2016. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2017.

Emory University reported no remaining Aclaris Therapeutics position as of Q1 2017 after selling out during the quarter.
Emory University sold 90,704 Aclaris Therapeutics shares in Q1 2017, an estimated $2.46M.
Emory University first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 1 quarter.
Emory University's Aclaris Therapeutics position peaked at $2.46M in Q4 2016.
110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2017.

Based on Emory University's 13F filing for Q1 2017, filed 11 May 2017.